Current adjuvants and new perspectives in vaccine formulation

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 1053-1061

  Montomoli, Emanuele ^a   Piccirella, Simona ^a   Khadang, Baharak ^a   Mennitto, Elisa ^a   Camerini, Roberto ^b   De Rosa, Alfonso ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Alum; EMA; FDA; ICH; MF59; regulatory procedures; TLR agonists; vaccine adjuvants

Indexed keywords

ADJUVANT; ALUMINUM SALT; CHITOSAN; ISCOM; LIPOSOME; MIFAMURTIDE; QS 21; QUIL A; RECOMBINANT CYTOKINE; SAPONIN DERIVATIVE; SQUALENE; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR AGONIST; VACCINE; VIROSOME;

DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GRANULOMA; HEALTH CARE ORGANIZATION; HEMOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; INJECTION SITE PAIN; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; DRUG COMPOUNDING; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; T-LYMPHOCYTES; VACCINATION; VACCINES;

EID: 80051499232     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.48     Document Type: Review

References (65)

1. Wack A, Rappuoli R. Vaccinology at the beginning of the 21st Century. Curr. Opin. Immunol. 17(4), 411-418 (2005).
2. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2(9), 727-735 (2003). (Pubitemid 37361788)
3. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8(4), 279-289 (2008). (Pubitemid 351432799)
4. McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol. 8, 37 (2010).
5. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38(8), 2068-2071 (2008).
6. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009).
7. Morefeld GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13), 1588-1595 (2005). (Pubitemid 40203396)
8. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 69(2), 1151-1159 (2001). (Pubitemid 32109584)
9. Kool M, Soullié T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating infammatory dendritic cells. J. Exp. Med. 205(4), 869-882 (2008). (Pubitemid 351549884)
10. Seubert A, Monaci E, Pizza M et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180(8), 5402-5412 (2008).
11. Eisenbarth SC, Colegio OR, O'Connor W et al. Crucial role for the Nalp3 infammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008). (Pubitemid 351871731)
12. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009).
13. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 95(2), 157-168 (1986). (Pubitemid 17229409)
14. Higgins DA, Carlson JR, Van Nest G. Mf59 adjuvant enhances the immunogenicity of infuenza vaccine in both young and old mice. Vaccine 14(6), 478-484 (1996).
15. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. Mf59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995).
16. Podda A, Del Giudice G. Mf59-adjuvanted vaccines: increased immunogenicity with an optimal safety profle. Expert Rev. Vaccines 2(2), 197-203 (2003).
17. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N. Trial of 2009 infuenza a (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424-2435 (2009).
18. Straus SE, Wald A, Kost RG et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins d and b: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176(5), 1129-1134 (1997). (Pubitemid 27460974)
19. Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769-2778 (1999). (Pubitemid 29323002)
20. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P. Human immunodefciency virus type 1 (HIV-1) gp120-specifc antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184(10), 1331-1335 (2001). (Pubitemid 33055581)
21. Childers NK, Miller KL, Tong G, Llarena JC, Greenway T, Ulrich JT. Adjuvant activity of monophosphoryl lipid a for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun. 68(10), 5509-5516 (2000).
22. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R. Immunogenicity and protectivity of a new liposomal hepatitis a vaccine. Vaccine 15(11), 1209-1213 (1997). (Pubitemid 27372102)
23. Calcagnile S, Zuccotti GV The virosomal adjuvanted infuenza vaccine. Expert Opin. Biol. Ther. 10(2), 191-200 (2010).
24. + T cells and induce potent antitumor immunity. J. Immunol. 177(4), 2324-2330 (2006). (Pubitemid 44200992)
25. Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14(10), 982-986 (1996). (Pubitemid 26271071)
26. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol. Immunol. 42(3), 289-294 (2005). (Pubitemid 39626760)
27. Tay EH, Garland S, Tang G et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the asia-pacifc region. Int. J. Gynaecol. Obstet. 102(3), 275-283 (2008).
28. Harper DM, Franco EL, Wheeler CM et al. Sustained effcacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
29. Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological activity of chitin and its derivatives. Vaccine 2(1), 93-99 (1984). (Pubitemid 15167639)
30. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis flamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16(20), 2039-2046 (1998). (Pubitemid 28473954)
31. McNeela EA, Mills KH. Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Deliv. Rev. 51(1-3), 43-54 (2001). (Pubitemid 32763071)
32. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from quillaja saponaria molina cortex. J. Immunol. 146(2), 431-437 (1991).
33. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 27(33), 4388-4401 (2009).
34. Morein B, Hu KF, Abusugra I. Current status and potential application of ISCOMS in veterinary medicine. Adv. Drug Deliv. Rev. 56(10), 1367-1382 (2004). (Pubitemid 38748821)
35. Wikman M, Friedman M, Pinitkiatisakul S et al. General strategies for effcient adjuvant incorporation of recombinant subunit immunogens. Vaccine 23(17-18), 2331-2335 (2005). (Pubitemid 40341478)
36. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig Drugs 7(9), 1475-1482 (1998). (Pubitemid 28408808)
37. Alonso PL, Sacarlal J, Aponte JJ et al. Effcacy of the RTS,S/AS02A vaccine against plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004). (Pubitemid 39370716)
38. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5(10), 987-995 (2004). (Pubitemid 41057715)
39. Koyama S, Coban C, Aoshi T, Horii T, Akira S, Ishii KJ. Innate immune control of nucleic acid-based vaccine immunogenicity. Expert Rev. Vaccines 8(8), 1099-1107 (2009).
40. Baldridge JR, Crane RT. Monophosphoryl lipid a (MPL) formulations for the next generation of vaccines. Methods 19(1), 103-107 (1999). (Pubitemid 29497759)
41. Di Paolo D, Lenci I, Cerocchi C et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl. Int. 23(11), 1105-1112 (2010).
42. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines 8(12), 1663-1679 (2009).
43. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 68(3), 359-372 (2008). (Pubitemid 351225812)
44. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insuffciency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther. 8(2), 235-247 (2008). (Pubitemid 351233716)
45. Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23(32), 4148-4157 (2005). (Pubitemid 40814590)
46. Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect. 7(5-6), 922-931 (2005). (Pubitemid 40826661)
47. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 (5), 244-249 (2005). (Pubitemid 40544642)
48. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471-484 (2006). (Pubitemid 44136959)
49. Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and effcacy. Expert Opin. Biol. Ther. 7(11), 1731-1737 (2007). (Pubitemid 350157498)
50. + T cell responses. J. Immunol. 174(12), 7676-7683 (2005). (Pubitemid 40806272)
51. Huang SJ, Hijnen D, Murphy GF et al. Imiquimod enhances IFN-g production and effector function of T cells infltrating human squamous cell carcinomas of the skin. J. Invest. Dermatol. 129(11), 2676-2685 (2009).
52. Heath AW. Cytokines as immunological adjuvants. Pharm. Biotechnol. 6, 645-658 (1995).
53. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71(8), 4780-4788 (2003). (Pubitemid 36919948)
54. Verastegui E, Barrera JL, Zinser J et al. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int. J. Immunopharmacol. 19(11-12), 619-627 (1997). (Pubitemid 28270796)
55. Hadden JW. T-cell adjuvants. Int. J. Immunopharmacol. 16(9), 703-710 (1994). (Pubitemid 24271862)
56. Goldstein AL, Low TL, McAdoo M et al. Thymosin a1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl Acad. Sci. USA 74(2), 725-729 (1977). (Pubitemid 8038798)
57. Peng Y, Chen Z, Yu W et al. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol. Int. 32(10), 1265-1271 (2008).
58. Romani L, Bistoni F, Gaziano R et al. Thymosin a 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103(11), 4232-4239 (2004). (Pubitemid 38685368)
59. Garaci E, Favalli C, Pica F et al. Thymosin a 1: From bench to bedside. Ann. NY Acad. Sci. 1112, 225-234 (2007).
60. Garaci E, Thymosin a1: a historical overview. Ann. NY Acad. Sci. 1112, 14-20 (2007).
61. Naylor PH, Hadden JW. T cell targeted immune enhancement yields effective T cell adjuvants. Int. Immunopharmacol. 3(8), 1205-1215 (2003). (Pubitemid 36830861)
62. Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 23(24), 3210-3222 (2005).
63. Sesardic D, Dobbelaer R. European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 22(19), 2452-2456 (2004). (Pubitemid 38757344)
64. Robert Edelma. An overview of adjuvant use. In: Vaccine Adjuvants, Preparation Methods and Research Protocols. Derek T, O'Hagan (Eds). Humana Press, Totowa, NJ, USA, 1-28 (2000).
65. Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28(3), 279-284 (1991).